13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
26 檔
57.6%
As reported in its official Q1 2026 Form 13F filing, Acuta Capital Partners, LLC's tracked investment portfolio stood at $143.5M with 26 total positions.
In Q1 2026, Acuta Capital Partners, LLC adopted a defensive or profit-taking posture, trimming 13 positions and completely liquidating 9 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 19.45% | -0.13% | +2.25% | |
| 2 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 18.59% | -18.59% | EXIT | |
| 3 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 8.37% | +6.59% | — | |
| 4 | TNGX | Tango Therapeutics Inc | Stock-Other | 6.57% | +1.95% | +56.27% | |
| 5 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 5.81% | -1.27% | +32.58% | |
| 6 | STRO | Sutro Biopharma Inc | Stock-Other | 4.77% | +1.48% | +299.44% | |
| 7 | ERAS | Erasca Inc | Stock-Other | 4.08% | -0.69% | — | |
| 8 | SRZN | Surrozen Inc | Stock-Other | 3.58% | -0.44% | -3.12% | |
| 9 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.57% | +0.07% | -43.77% | |
| 10 | CMPX | Compass Therapeutics Inc | Stock-Other | 3.19% | -2.28% | -22.34% | |
| 11 | NERV | Minerva Neurosciences Inc | Stock-Other | 3.04% | -0.30% | — | |
| 12 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.54% | +0.39% | +223.48% | |
| 13 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.44% | +0.60% | -3.32% | |
| 14 | OCS | Oculis Holding AG | Stock-Other | 1.86% | -1.86% | EXIT | |
| 15 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.80% | -1.80% | EXIT | |
| 16 | ✓ | 4d Molecular Therapeutics Inc | Stock-Other | 1.60% | -1.60% | EXIT | |
| 17 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.49% | +0.61% | -54.67% | |
| 18 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.40% | +1.27% | -3.38% | |
| 19 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.15% | -1.15% | EXIT | |
| 20 | DSGN | Design Therapeutics Inc | Stock-Other | 1.10% | +1.75% | -3.32% | |
| 21 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.94% | -0.10% | -3.14% | |
| 22 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.80% | -0.80% | EXIT | |
| 23 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.65% | +1.75% | — | |
| 24 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.51% | +0.14% | -3.60% | |
| 25 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.41% | -0.41% | EXIT | |
| 26 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.27% | -0.27% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | +4.9% | +56.27% | Add |
| 2 | STRO | Sutro Biopharma Inc | +4.2% | +299.44% | Add |
| 3 | ERAS | Erasca Inc | +4.1% | NEW | New buy |
| 4 | PRAX | Praxis Precision Medicines I | +2.8% | +2.25% | Add |
| 5 | WHWK | Whitehawk Therapeutics Inc | +2.8% | — | Unchanged |
| 6 | MLTX | Moonlake Immunotherapeutics | +2% | +223.48% | Add |
| 7 | ✓ | 4d Molecular Therapeutics Inc | +1.6% | NEW | New buy |
| 8 | RVMD | Revolution Medicines Inc | +1.4% | +209.94% | Add |
| 9 | DRUG | Bright Minds Biosciences Inc | +1.3% | +32.58% | Add |
| 10 | IDYA | Ideaya Biosciences Inc | +1.2% | NEW | New buy |
| 11 | 430 | Terns Pharmaceuticals Inc | +1.1% | -22.18% | Trim |
| 12 | NERV | Minerva Neurosciences Inc | +1.1% | — | Unchanged |
| 13 | SRZN | Surrozen Inc | +0.8% | -3.12% | Trim |
| 14 | TRDA | Entrada Therapeutics Inc | +0.8% | NEW | New buy |
| 15 | AVTX | Avalo Therapeutics Inc | +0.7% | NEW | New buy |
| 16 | OCS | Oculis Holding AG | +0.5% | -3.38% | Trim |
| 17 | UTHR | United Therapeutics CORP | +0.2% | -3.14% | Trim |
| 18 | DSGN | Design Therapeutics Inc | +0.1% | -3.32% | Trim |
| 19 | LBRX | Lb Pharmaceuticals Inc | +0.1% | -3.60% | Trim |
| 20 | UNCY | Unicycive Therapeutics Inc | 0% | -3.38% | Trim |
| 21 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | EXIT | Sold out |
| 22 | MAZE | Maze Therapeutics Inc | -0.2% | -3.33% | Trim |
| 23 | TSHA | Taysha Gene Therapies Inc | -0.3% | -3.38% | Trim |
| 24 | ARGX | Argenx Se - Adr | -0.3% | -3.32% | Trim |
| 25 | KTTA | Pasithea Therapeutics CORP | -0.4% | EXIT | Sold out |
| 26 | DNTH | Dianthus Therapeutics Inc | -0.5% | EXIT | Sold out |
| 27 | VSTM | Verastem Inc | -0.8% | EXIT | Sold out |
| 28 | CMPX | Compass Therapeutics Inc | -0.8% | -22.34% | Trim |
| 29 | INBX | Inhibrx Biosciences Inc | -0.9% | EXIT | Sold out |
| 30 | AMLX | Amylyx Pharmaceuticals Inc | -1.2% | -54.67% | Trim |
| 31 | ZYME | Zymeworks Inc | -1.4% | EXIT | Sold out |
| 32 | INSM | Insmed Inc | -3.1% | EXIT | Sold out |
| 33 | JAZZ | Jazz Pharmaceuticals plc | -3.4% | EXIT | Sold out |
| 34 | OCUL | Ocular Therapeutix Inc | -5.1% | -43.77% | Trim |
| 35 | CDTX | Cidara Therapeutics Inc | -13.4% | EXIT | Sold out |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 26 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, 430, WHWK) accounted for 57.6% of total reported equity market value during Q1 2026.
Top New Position Initiated
ERAS
市值: $5.7M
Top Position Liquidated / Trimmed
CDTX
前期市值: $19.7M
During Q1 2026, Acuta Capital Partners, LLC's top holdings by market value included PRAX (19.4%)、430 (18.6%)、WHWK (8.4%). The largest single position, PRAX, represented 19.4% of total portfolio value.
In Q1 2026, Acuta Capital Partners, LLC made 33 total portfolio adjustments, initiating 5 new buys, adding to 6 positions, trimming 13 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.